BeOne Medicines Receives FDA Fast Track Designation for BGB-B2033 in Liver Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- FDA Fast Track Designation: BeOne Medicines' BGB-B2033 bispecific antibody has received FDA Fast Track Designation, indicating its significant potential in treating hepatocellular carcinoma (HCC), particularly in a landscape with limited existing treatment options.
- Clinical Trial Progress: BeOne is currently conducting a global, multi-center Phase 1 clinical trial to evaluate the safety and anti-tumor activity of BGB-B2033, aiming to provide new treatment options for HCC patients and meet the urgent market demand for innovative therapies.
- Hepatocellular Carcinoma Landscape: HCC is the sixth most common cancer worldwide, with new cases expected to double by 2050 and current five-year survival rates below 20%, highlighting the urgent need for new therapies, which BGB-B2033 aims to address.
- Strategic Company Positioning: BeOne Medicines is committed to developing more accessible cancer treatment options, and the Fast Track Designation for BGB-B2033 not only enhances the company's competitive edge but also may accelerate its positioning in the global oncology market.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
- BLA Acceptance: The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated advanced non-small cell lung cancer, with a decision expected by November 14, 2026.
- Clinical Trial Results: The Phase 3 HARMONi trial showed a median overall survival of 16.8 months for ivonescimab plus chemotherapy compared to 14.1 months for chemotherapy alone, indicating significant therapeutic potential.
- Future Research Plans: Summit anticipates completing enrollment in the squamous cohort of the HARMONi-3 trial in the first half of 2026, with primary endpoint analysis expected in the second half of 2026, further advancing ivonescimab's clinical development.
- New Study Initiation: The company has initiated the Phase 3 HARMONi-GI3 study for first-line unresectable metastatic colorectal cancer, aiming to expand ivonescimab's clinical development program to meet market needs.
Continue Reading
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
- Market Volatility: On Wednesday, the S&P 500 and Dow reversed from their highs, indicating a shift in market sentiment that could influence short-term investor decisions.
- Nasdaq Performance: Although the Nasdaq index initially gained, it ultimately narrowed its gains, reflecting the volatility of tech stocks and the uncertainty in the market.
- Buy Signals: Eli Lilly and Google flashed buy signals, potentially attracting investor interest in these companies' future growth prospects, especially in the current market environment.
- Investor Sentiment: The overall market reversal may lead investors to reassess their risk appetite, thereby affecting capital flows and market dynamics.
Continue Reading